INTRODUCTION
Trichomonas vaginalis is the most common curable STI worldwide, with regional prevalence rates in women ranging from 5% in the Western Pacific to 18% in Africa. [1] [2] [3] [4] [5] Each year, 25 million T. vaginalis infections occur during pregnancy, with women in sub-Saharan Africa disproportionately affected compared with other regions. 6 7 T. vaginalis is associated with pelvic inflammatory disease and risk of HIV acquisition in women. [8] [9] [10] [11] [12] Several individual studies [13] [14] [15] [16] [17] [18] [19] and two meta-analyses 20 21 implicate T. vaginalis infection in poor infant outcomes including preterm birth, small for gestational age (SGA), premature rupture of membranes and low birth weight.
Hormonal changes during pregnancy and post partum may alter susceptibility to T. vaginalis infection or persistence of infections. 2 22 Changes in sexual behaviour may also influence T. vaginalis exposure during and after pregnancy. Crosssectional studies have estimated T. vaginalis prevalence between 15% and 32% in peripartum African cohorts, and older age, younger age at sexual debut, higher education, being married and comorbid STIs have been all been associated with prevalent T. vaginalis infection. [23] [24] [25] [26] In non-pregnant African women, male partner circumcision status has been associated with lower T. vaginalis incidence; however, this relationship has not been evaluated in pregnant and postpartum populations. 23 27 In addition, there are limited data on T. vaginalis incidence and cofactors among pregnant and postpartum African women. 28 29 We evaluated incidence and correlates of T. vaginalis among pregnant and postpartum women in Western Kenya.
METHODS

Design and participants
We used data from a longitudinal study investigating rates and cofactors of acute HIV infection among HIV-uninfected women at two rural antenatal care (ANC) clinics in Western Kenya (the Mama Salama Study) conducted between May 2011 and July 2014. Recruitment, eligibility criteria and follow-up procedures for the parent study have been previously described. 30 Briefly, pregnant women were eligible if they were ≥14 weeks gestation, were ≥14 years old, had negative rapid HIV test at enrolment or within the 3 months prior, planned to remain in the study area for the duration of pregnancy through 9 months post partum, were willing to have a home visit and were not enrolled in another research study.
Study procedures
Women attended follow-up visits during pregnancy (20, 24, 32 and 36 weeks gestation) and post partum (2, 6, 10 and 14 weeks; 6 and 9 months). At each study visit, standardised questionnaires were administered by study nurses on socio-demographic factors, reproductive history, sexual behaviour, hormonal contraception and condom use, medical history and genital symptoms. Male partner characteristics were reported by participating women. Women self-collected vaginal swabs, had physical exams at each study visit and had pelvic exams at enrolment, 28 weeks gestation, 6 weeks post partum and 6 months post partum. Swabs were not collected during menstruation. All women with T. vaginalis infection were treated with metronidazole (one dose of 2 g) per the WHO and Kenya Ministry of Health's national treatment guidelines for laboratory-confirmed genital infections in pregnancy.
w1 w2 Antimicrobials were administered at no cost as part of the study. Women were counselled to have their partner come to the study clinic for complete STI testing and treatment. 
Laboratory procedures
Chlamydia trachomatis and Neisseria gonorrhoeae were assessed at enrolment using endocervical samples for nucleic acid amplification tests (NAATs) with the APTIMA Combo 2 Assay (HOLOGIC/GEN-PROBE, San Diego, California, USA). Syphilis serology was based on rapid plasma reagin tests conducted at enrolment as part of routine ANC and abstracted from maternal child health booklets or conducted by study staff if the test was not performed. Candidiasis and bacterial vaginosis (BV) were assessed at every study visit. Candidiasis was detected by direct microscopy after addition of 10% KOH. Vaginal Gram stained slides were evaluated using Nugent's criteria, with BV defined as a score of 7-10. T. vaginalis was assessed at every study visit and infection was determined by detection of motile trichomonads using wet mount microscopy. All laboratory procedures were performed by study laboratory technicians, who had received standardised training on microscopy. Quality assurance was performed monthly by comparing results in a subset of samples with an external lab. Genital symptoms for T. vaginalis were defined as abnormal discharge, foul odour, vaginal itching or vaginal burning.
Statistical analysis
HIV-uninfected women with baseline T. vaginalis assessment and at least one reassessment of T. vaginalis at study follow-up were included in the analyses. Women who acquired HIV infection during the study were excluded to control for potential underlying differences in that group. Incident T. vaginalis was defined as a new infection detected among women who did not have prevalent T. vaginalis at enrolment. Timing of incident T. vaginalis was estimated to be at the midpoint between the preinfection visit and the visit at which the infection was detected.
Cox proportional hazards models were used to determine correlates of time-to-first incident T. vaginalis infection. All models used robust SEs. Variables associated with T. vaginalis (α=0.10) in the univariate analyses were included in the multivariate models and were tested for collinearity. Potential correlates included socio-demographic and sexual partnership characteristics, hormonal contraception and condom use, other curable STIs (C trachomatis, N gonorrhoeae and syphilis), sexual behaviours and vaginal washing or drying practices. Unprotected sex, number of sexual partners, BV, candidiasis, vaginal washing and drying, and postpartum hormonal contraception use were included as time varying. Women were classified as hormonal contraception nonusers if no hormonal contraception was used, including women that did not use another form of contraception.
We conducted sensitivity analyses to reduce potential misclassification of undetected prevalent infections as incident infections due to low sensitivity of wet mount microscopy.
w4-w6
We repeated all analyses excluding women with T. vaginalis detected at enrolment and/or at first postenrolment visit to evaluate whether T. vaginalis incidence and correlates would remain similar to our primary analyses. Data were analysed using Stata V.13.1/MP for Windows (Stata, College Station, Texas, USA).
RESULTS
Overall, 1271 women (97% of women in the parent study) met criteria for inclusion for this analysis; women were excluded due to HIV infection (n=25) and lack of T. vaginalis results (n=8). Most women were married (78%), median age was 22 years (IQR 19-27), median gestational age at enrolment was 22 weeks (IQR [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] and median level of highest education completed was 8 years (IQR 7-10) (table 1). Among women with male partners, median partnership duration was 4 years (IQR 1-7) and one-third (31%) reported their male partner was circumcised. No male partners were reported to have been circumcised during follow-up. At enrolment, about half (55%) of women reported condomless sexual intercourse in the last 30 days. BV (23%) and candidiasis (25%) were the most common genital infections detected at enrolment. Other curable STIs were detected in 109 (9%) women (C trachomatis 5%, N gonorrhoeae 3% and syphilis 1%).
T. vaginalis prevalence and incidence
At enrolment, 81 (6%) of women had prevalent T. vaginalis; 16 (20%) of whom were coinfected with another curable STI. During 1079 total person-years of follow-up (median 0.9 years, IQR 0.8-1.1), 112 incident infections of T. vaginalis were detected (44 in pregnancy and 68 post partum), resulting in an overall incidence of 10.4 per 100 person-years (figure 1). Women with either prevalent or incident T. vaginalis infection were three times as likely to report genital symptoms at any time during follow-up compared with women that never had T. vaginalis (OR 3.08, 95% CI 1.92 to 4.94, p<0.001). However, symptoms were only reported by 41 (51%) women with prevalent and 9 (8%) women with incident T. vaginalis infections at the time of detection.
Correlates of T. vaginalis incidence
Incidence of T. vaginalis was higher in pregnancy versus post partum (22.3 vs 7.7 per 100 person-years, respectively, p<0.001, table 2). In unadjusted models, male circumcision (HR 0.48, 95% CI 0.29 to 0.81), pregnancy (HR 3.08, 95% CI 1.93 to 4.91) and detection of other curable STIs (HR 2.03, 95% CI 1.14 to 3.65) were associated with incident T. vaginalis. Among postpartum women, we did not detect an association between those using implant, injectable or oral, hormonal contraception and incident T. vaginalis infection compared with non-users (HR 0.86, 95% CI 0.27 to 2.72, p=0.795; HR 0.84, 95% CI 0.34 to 2.09, p=0.713; HR 0.92, 95% CI 0.28 to 2.97, p=0.886, respectively).
In the multivariate model, risk of incident T. vaginalis was threefold higher during pregnancy compared with post partum (adjusted HR (aHR) 3.68, 95% CI 1.90 to 7.15, p≤0.001) after adjusting for employment, male partner circumcision and infection with other STIs during pregnancy. Women with circumcised male partners had a 58% lower risk of incident T. vaginalis compared with women with uncircumcised partners (aHR 0.42, 95% CI 0.23 to 0.76, p=0.004). Risk of incident T. vaginalis was also lower among women who were employed versus unemployed (aHR 0.49, 95% CI 0.31 to 0.79, p=0.003) and higher among women with other curable STIs (aHR 2.10, 95% CI 1.16 to 3.79, p=0.014). When non-T. vaginalis STIs were individually assessed, only N gonorrhoeae was significantly associated with incident T. vaginalis infection (aHR 2.97, 95% CI 1.49 to 5.94, p=0.002), though infection with C trachomatis trended towards an association (aHR 1.82, 95% CI 0.90 to 3.69, p=0.097); syphilis was not associated with incident T. vaginalis (aHR 2.56, 95% CI 0.62 to 10.46, p=0.192).
Sensitivity analyses
In sensitivity analyses, we excluded women with T. vaginalis detected at enrolment and/or at first postenrolment visit. Overall T. vaginalis incidence was comparable to the primary results (6.8 per 100 person-years), though incidence during pregnancy was lower (9.5 per 100 person-years) than in the primary analysis. Pregnancy and STIs remained associated with increased risk of incident T. vaginalis (aHR 4.97, 95% CI 2.41 to 10.24, p≤0.001 and aHR 2.09, 95% CI 1.04 to 4.22, p=0.040, respectively). Male circumcision also remained associated with reduced risk (aHR 0.42, 95% CI 0.21 to 0.87, p=0.019). Other cofactors were not significantly associated with incident T. vaginalis (data not shown).
DISCUSSION
In this prospective study of HIV-uninfected pregnant and postpartum Kenyan women, T. vaginalis infection was relatively common. Incidence of T. vaginalis during follow-up was high, with increased T. vaginalis incidence during pregnancy compared with the postpartum period. Infection with other STIs at enrolment was associated with increased risk of incident T. vaginalis. In multivariate analyses, employment and male partner circumcision were associated with a lower risk of incident T. vaginalis. These data suggest that there is persistent risk of T. vaginalis during pregnancy and post partum, and that male circumcision is a potential modifiable factor that may decrease risk of T. vaginalis in this period.
Male circumcision has been associated with decreased risk of human papillomavirus, genital ulcers, herpes simplex virus 2, BV, syphilis and T. vaginalis in women in randomised clinical trials (RCTs).
27 w7-w13 One RCT from Uganda reported a 48% reduction of T. vaginalis associated with male partner circumcision, similar to our findings. 27 In contrast, an observational study of HIV-uninfected women from Zimbabwe, Uganda and Thailand reported no association between male partner circumcision and incident T. vaginalis.
w11 Male circumcision may decrease men's risk of T. vaginalis infection, and, in turn, reduce the probability that female partners are exposed to T. vaginalis. Additionally, the moist subpreputial space in uncircumcised men may enhance survival of trichomonads; thus, foreskin removal may reduce male-to-female transmissions of T. vaginalis.
27 w11 w14 We are not aware of other studies examining STI acquisition and male circumcision specifically during or after pregnancy, a critical period of potential vulnerability with implications for pregnancy outcomes. Male circumcision promotion may confer benefits in preventing T. vaginalis. Thus, additional benefits of expanding male circumcision as a strategy to prevent HIV acquisition may include prevention of transmission of other STIs, such as T. vaginalis.
Our finding that other curable STIs increased risk of acquiring T. vaginalis infection is consistent with other studies in nonpregnant women that have found recent infection with STIs Missing data not shown; all characteristics assessed at baseline unless indicated. *Among women reporting current relationship. †Male circumcision and HIV status of male partners reported by female partner. ‡Among women with ≥1 children. §Among postpartum women only; current use at 9 months post partum. ¶Includes C trachomatis, N gonorrhoeae and syphilis. Similar to other studies, we found socio-demographic and relationship characteristics, including partner characteristics, were associated with T. vaginalis. 24 25 w17 Women with lower socioeconomic status may have less access to STI preventative information and care or may have less power in relationships to negotiate safer sexual practices due to economic dependence on male partners. w18 Maximal cure rates in infected women are achieved with concurrent treatment of their sexual partners. Treatment of male partners is critical to preventing reinfection with T. vaginalis, especially during pregnancy when prevention has immediate benefits for mothers and infants. We have previously reported results from a pilot study of patient-delivered partner treatment for management of T. vaginalis, which demonstrated acceptability and feasibility among pregnant and postpartum Kenyan women. w3 Further evaluation of this model will be useful in settings with high T. vaginalis prevalence.
Prevalence of T. vaginalis infection at enrolment was lower in our HIV-uninfected cohort than some previous studies in African pregnant and postpartum women ( prevalence 15-32%). 24 25 28 w20 Previous studies did not exclude HIV-infected women and used a variety of T. vaginalis diagnostics, including more sensitive assays that may account for differences with our results. However, a recent study of HIV-uninfected, nonpregnant women from Malawi, South Africa, Uganda and Zimbabwe reported a T. vaginalis prevalence of 7%, similar to our findings.
w21 Our estimate of incidence of T. vaginalis infection during pregnancy of 22.8 per 100 person-years was similar to another study of HIV-uninfected women in South Africa, which reported an incidence of 17.6 per 100 person-years. 28 We found increased incidence of T. vaginalis in pregnancy compared with post partum. Hormonal alterations unique to pregnancy may alter susceptibility to T. vaginalis, similar to other infectious diseases. 2 22 w22 Among pregnant and postpartum women in other studies, 72-88% of T. vaginalis infections were asymptomatic, similar to our cohort in which over half of prevalent infections were asymptomatic. 24 28 We also found that incident infections were less frequently symptomatic, which could be due to early detection as symptoms can arise up to 28 days after initial infection in women. Thus, many early T. vaginalis infections may go undetected and untreated in settings with exclusively syndromic management.
Our findings raise important questions about the diagnosis and management of T. vaginalis infection in pregnant and postpartum women in high-prevalence settings particularly in areas of high HIV risk. Meta-analyses have found associations of T. vaginalis infection in pregnancy with premature birth, SGA and premature rupture of membranes. 20 However, it has not been clear that treatment of T. vaginalis will decrease this risk. One systematic review suggested that treatment of T. vaginalis during pregnancy may increase incidence of preterm birth, 21 perhaps due to use of higher dosages of metronidazole than typically recommended in included studies or coinfection with other STIs. 20 25 More recent studies, including an RCT, noted no association of T. vaginalis infection or treatment in pregnancy with preterm birth. 25 w23 w24 In our study, women were regularly screened for T. vaginalis and women with confirmed T. vaginalis were treated with metronidazole according to national guidelines. The benefit and cost-effectiveness of routine screening for T. vaginalis in asymptomatic pregnant women has not been established. However, prenatal T. vaginalis screening and prompt treatment are recommended for HIV-infected pregnant women because T. vaginalis infection is a risk factor for vertical transmission of HIV. Our results suggest that T. vaginalis incidence is high during pregnancy and often asymptomatic, and will thus requires alternative approaches to syndromic management for adequate detection and treatment.
Our study has some limitations. We used microscopy for T. vaginalis detection, which is less sensitive for T. vaginalis detection than PCR or other types of NAAT. 24 25 w4-w6 w17 However, this approach is similar to other studies in Africa and is easy to contextualise given the same approach. 24 25 w17 While some studies from Africa have demonstrated comparable specificity of wet mount to PCR and other diagnostic methods for T. vaginalis, w25 lower sensitivity would result in underestimates of prevalence and incidence in our cohort. We did conduct exploratory analyses to estimate the potential impact of misclassifying undetected prevalent infections, and results were similar in both analyses. We relied on women's report of male partner circumcision status, which may have introduced exposure misclassification based on the accuracy of women's report. While studies from Zambia and Swaziland suggest that women overestimate male partner circumcision, w26 recent data from Uganda, a setting with male circumcision sensitisation programmes more similar to Western Kenya, suggest <10% of women misreport male partner circumcision status.
w27 Therefore, misreporting likely did not substantially influence our results. Finally, other curable STIs were only assessed at baseline and we were unable to evaluate the relationship of incident STIs on T. vaginalis.
In summary, our results suggest that pregnant and postpartum women frequently acquire T. vaginalis and most infections are asymptomatic, supporting scale-up of improved diagnostic techniques for T. vaginalis infections in this group. 28 We found male circumcision was associated with reduced T. vaginalis incidence, adding to the body of evidence that male circumcision prevents STIs in female partners. Our results suggest that male circumcision could reduce T. vaginalis incidence and related sequelae among pregnant and postpartum female partners. Improved T. vaginalis control through detection of asymptomatic infections and reduced male-to-female transmissions could have important implications, particularly in settings of high STI morbidity and where poor birth outcomes persist as a public health problem.
Key messages
▸ Pregnant and postpartum women frequently acquire
Trichomonas vaginalis and most infections are asymptomatic. ▸ Male circumcision could reduce T. vaginalis incidence among pregnant and postpartum female partners.
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